Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1894891 | 0.90 | LMNA (0.50) | CYP1A2CYP2C19CYP2D6SMN1; SMN2MAPT | |
| SCHEMBL1893597 | 0.87 | MAPT (0.51) | CYP1A2CYP2C19CYP2D6SMN1; SMN2MAPT | |
| SCHEMBL1894551 | 0.86 | SMN1; SMN2 (0.56) | CYP1A2CYP2C19CYP2D6SMN1; SMN2MAPT | |
| SCHEMBL1007194 | 0.85 | ALDH1A1 (0.56) | CYP1A2CYP2C19SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL1009404 | 0.84 | SMN1; SMN2 (0.55) | CYP1A2CYP2C19SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL1007223 | 0.84 | MAPT (0.53) | CYP1A2CYP2C19SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL1009492 | 0.83 | MAPT (0.50) | CYP1A2CYP2C19CYP2D6SMN1; SMN2MAPT | |
| SCHEMBL1895516 | 0.83 | SMN1; SMN2 (0.52) | CYP1A2CYP2C19CYP2D6SMN1; SMN2MAPT | |
| SCHEMBL1897449 | 0.82 | GRIA2 (0.61) | CYP2D6SMN1; SMN2MAPTALDH1A1HTT | |
| SCHEMBL1007672 | 0.82 | GRIA2 (0.61) | CYP1A2CYP2C19CYP2D6SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-19 | — | — | US | disclosed |
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-19 | — | — | US | disclosed |
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | GRIN1, GRM1, GRIK1 | CYP1A2 2476/4885CYP2C19 3268/4885CYP2D6 3476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.